Through 3 years , rates of AEs per 100 patient-years of follow-up ( / 100 patient-yrs ) ( 45 mg : 305.2 / 100 patient-yrs ; 90 mg : 305.9 / 100 patient-yrs ) and SAEs ( 45 mg : 6.8 / 100 patient-yrs ; 90 mg : 8.2 / 100 patient-yrs ) were comparable between ustekinumab doses .
